



Case Report

## Enucleation Combined with Giant Marsupilization Maxillary Radicular Cyst

*Aris Setyawan, Kiki Melinda Butar-Butar\*, Vega Melati Samudera, Via Yovita Alpiani, Bitha Ariyani, Athalaila Sakuntala*

*Department of Oral Surgery Professional Dentist Education, Faculty of Medicine, Diponegoro University, Jl. Prof. Mr. Sunario, Tembalang, Tembalang District, Central Java, 50275 Semarang, Indonesia*

### ARTICLE INFORMATION

Received: September 01, 2023  
 Revised: September 17, 2023  
 Accepted: September 29, 2023  
 Available online: October 20, 2023

### KEYWORDS

*Risk Characterization; medical history; Comorbidity; Treatment Status; Treatment History*

### CORRESPONDING AUTHOR

**Kiki Melinda Butarbutar**

E-mail: [kikimelindabutar.undip@gmail.com](mailto:kikimelindabutar.undip@gmail.com)

### A B S T R A K

BRadicular cysts are odontogenic inflammatory cysts, which are located at the apex of non-vital teeth. Radiographically, this cyst appears as a round radiolucency with firm borders. Radicular cysts enlarge progressively asymptotically, until the cyst becomes quite large. This case report discusses a large radicular cyst in the maxilla, which extended from the region of teeth 24 to 13 past the midline of the maxilla. Of the several treatment options available for the treatment of large radicular cysts in the maxilla, the method of enucleation combined with marsupialization and decompression while preserving the bony window as well as extraction of the infected tooth was applied to the patient in this case. This method was chosen with the aim of reducing the size of the cyst cavity and bone tissue defects, as well as triggering the growth of new bone tissue. The procedure was carried out successfully without any complications. Obturator installation was also carried out on the patient, and there was good tissue recovery after surgery.

## INTRODUCTION

Health issues, particularly in Indonesia, can result in extremely complex medical, social, economic, and cultural issues. To protect public health, reduce morbidity and mortality, halt transmission, and prevent OAT resistance, the management of tuberculosis prioritizes promotive and preventative aspects over curative and rehabilitative ones (9). The treatment history of tuberculosis is also essential for determining the severity of the disease in a person's body. There are multiple criteria for TB SO, including a history of treatment, TB relapse, TB drug failure, and discontinuation of TB treatment. In contrast, for TB RO patients, nine criteria have been established to determine which treatment regimen will be prescribed so that drug resistance does not develop beforehand. RO TB patients must also undergo an EKG, culture examination, LPA, and C-DST to determine drug sensitivity in the TB patient's body. This differs from SO TB patients, who only conduct fundamental examinations.

Other risk factors, such as diabetes mellitus (DM), can also increase the likelihood of contracting tuberculosis and even influence treatment outcomes. Diabetes mellitus, resulting in immunosuppression, is increasingly recognized as a risk factor for tuberculosis. DM increases the risk of developing tuberculosis by a factor of two to three, as well as the risk of treatment failure, recurrence, and mortality (4). The risk of developing tuberculosis depends on the concentration of inhaled bacteria, the length of time since infection, and the age of a person with a compromised immune system, such as HIV/AIDS, which facilitates the development of active TB. 10% of those contaminated with HIV who are also infected with tuberculosis will develop tuberculosis. But for HIV-positive individuals, the incidence of tuberculosis will increase. Those infected with HIV are 20–37 times more likely to contract tuberculosis than those without HIV; consequently, TB transmission in the community will increase. Without treatment, 50 percent of TB patients will perish, and this risk increases for HIV-positive patients. Similarly, 25% of PLHIV fatalities are caused by tuberculosis (9).

According to WHO data, the estimated number of persons diagnosed with tuberculosis worldwide in 2021 is 10.6 million, an increase of approximately 600,000 cases from 2020's estimated 10 million cases. Of the 10.6 million cases, 6.4 million (60.3%) had been recorded and were receiving treatment, while 4.2 million (39.5%) had not been discovered, diagnosed, or reported. According to the World Health Organization's (WHO) Global TB Report (7), Indonesia will be the second-largest contributor of tuberculosis (TB) patients after India in 2022, with 969,000 cases, or 350 per 100,000 population. (7) In 2019, West Sumatra Province recorded 11,115 TB cases (53%), while in 2020, there was a decrease of 6384 cases (27%), of which 5622 were in adults and 748 in children, with Padang City having the maximum number of cases with 1,662 (32%) cases. (3) Inadequate health services hinder the government's efforts to eradicate tuberculosis, which has become the focus of TB treatment. SDGS intends to eradicate tuberculosis by 2030, given current conditions. Indonesia has surpassed India as the nation with the most TB cases. Therefore, Indonesia strives to provide optimal TB health services in multiple regions, even during a pandemic. Consequently, the purpose of this study was to assess the risk characterization of treatment history and comorbidities on tuberculosis (TB) treatment status in West Sumatra Province in 2020–2021.

## METHOD

This investigation is an analytic case-control study using the retrospective cohort method. This investigation was conducted in the province of West Sumatra. The sampling technique utilized in this study is a straightforward random sampling technique. This study's population consisted of all TB SO and RO TB patients diagnosed in 2020 and 2021, for a total of 14795 individuals. This study's sample size was determined according to the adequacy of sample size in health studies. In this investigation, 161 TB RO patients and 161 TB SO patients served as samples. This study utilized the sample formula for assessing the adequacy of sample size in health investigations. The inclusion criteria for the cases in this research were all patients who tested positive for TB RO in West Sumatra Province in 2020 and 2021, while the exclusion criteria were incomplete TB data (no treatment history and comorbidities). The inclusion criteria for the controls in this analysis included TB SO patients who were recorded at SITB in 2020–2021, while the exclusion criteria included incomplete TB data (no treatment history) and comorbidities. In January 2023, this investigation was conducted in the province of West Sumatra. The instrument for research utilized secondary data obtained from the online TB information system. The analysis of the data employed univariate, bivariate, and multivariate methods. This statistical research test employs R software and R Studio.

## RESULT DAN DISCUSSION

### 1. Characteristics of Risk Factors Based on TB Treatment Status in West Sumatra Province in 2020-2021

In this study, TB treatment status was the dependent variable, while the independent variables were age, sex, Investigation of Contacts, New TB, Relapsed TB, Failed TB, Dropped Out TB, Diabetes mellitus, and HIV. The distribution of these variables is shown in the following table.

**Table 1. Characteristics of Risk Factors Based on TB Treatment Status in West Sumatra Province in 2020-2021**

Variable	TBC RO, N = 161 <sup>1</sup>	TBC SO, N = 161 <sup>1</sup>
<b>Gender</b>		
Male	111 (69%)	87 (54%)
Female	50 (31%)	74 (46%)
<b>Age</b>		
Children	2 (1.2%)	20 (12%)
Adult	159 (99%)	141 (88%)
<b>Investigation of contact</b>		
Yes	64 (40%)	120 (75%)
No	97 (60%)	41 (25%)
<b>The New TB</b>		
Yes	76 (47%)	153 (95%)
No	85 (53%)	8 (5.0%)
<b>Relapse TB</b>		
Yes	61 (38%)	5 (3.1%)
No	100 (62%)	156 (97%)
<b>Drug Failed TB</b>		
Yes	15 (9.3%)	1 (0.6%)
No	146 (91%)	160 (99%)
<b>TB Discontinued Medication</b>		
Yes	9 (5.6%)	2 (1.2%)
No	152 (94%)	159 (99%)
<b>Diabetes mellitus</b>		
Positive	10 (6.2%)	10 (6.2%)
Negative	21 (13%)	43 (27%)
Unknow	130 (81%)	108 (67%)
<b>HIV</b>		
Positive	1 (0.6%)	1 (0.6%)
Negative	17 (11%)	31 (19%)
Unknow	143 (89%)	129 (80%)

<sup>1</sup>n (%); Median (IQR)

**Table 2. Relationship between Age, Gender, Contact Investigations, Treatment History and Comorbidities on TB Treatment Status in West Sumatra Province in 2020-2021**

Variable	TBC RO	TBC SO	Total	OR	95% CI	p-value
<b>Age</b>						
Children (0-14 Years)	2 (1,2%)	20 (20%)	22 (21,2%)	0,09	0,01-0,31	0,001
Adult (<15 Years)	159 (99%)	141 (88%)	300 (78,8%)			
<b>Gender</b>						
Male	111 (34%)	87 (27%)	198 (61%)	1,89	1,20 – 2,99	0,006
Female	50 (16%)	74(23%)	124 (39%)			
<b>Contact Investigation</b>						
No	64 (20%)	120 (27%)	184 (57%)	0,23	0,14 – 0,36	<0,001
Yes	97 (16%)	41 (13%)	138 (43%)			
<b>Pulmonary TB</b>						
Yes	76 (24%)	153 (48%)	66 (20%)	0,05	0,02 – 0,10	<0,001
No	85 (26%)	8 (2,5%)	256 (80%)			
<b>TB Relapses</b>						
Yes	61 (19%)	5 (1,6%)	66 (20%)	19,0	8,11 – 55,9	<0,001
No	100 (31%)	156 (48%)	256 (80%)			

Variable	TBC RO	TBC SO	Total	OR	95% CI	p-value
<b>Treatment Failure</b>						
Yes	61 (19%)	5 (1,6%)	66 (20%)	16,4	8,11 – 55,9	<0,001
No	100 (31%)	156 (48%)	156 (80%)			
<b>Withdrawal from treatment</b>						
Yes	9 (3%)	2 (1%)	11 (3,4%)	4,71	1,19 – 31,2	0,050
No	152 (47%)	159 (47%)	311 (97%)			
<b>Diabetes Mellitus</b>						
Positive	10 (3%)	10 (3%)	20 (6%)	2,05	0,73 – 5,76	0,2
Negative	21 (7%)	43 (13%)	64 (20%)			
Unknown	130 (40%)	108 (34%)	238 (74%)			
<b>HIV</b>						
Positive	10 (0,3%)	1 (0,3%)	2 (0,6%)	1,82	0,07 – 48,1	0,7
Negative	17 (4,3%)	31 (9,6%)	48 (15%)			
Unknow	143 (44%)	129 (40%)	272 (84%)			

**Table 3. Final Models**

Variable	N	Bivariate			Multivariate		
		OR <sup>1</sup>	95%CI <sup>1</sup>	P-Value	AOR <sup>1</sup>	95%CI <sup>1</sup>	P-Value
<b>Contact Investigation</b>	322	0,23	0,14 – 0,36	<0,001	0,33	0,19 – 0,56	<0,001
<b>Pulmonary TB</b>	322	0,23	0,02 – 0,10	<0,001	0,06	0,03 – 0,13	<0,001
<b>Age</b>	322	0,23	0,01 – 0,31	0,001	0,16	0,02 – 0,61	0,020

<sup>1</sup>OR = Odds Ratio, CI = Confidence Interval

**2. Assessing West Sumatra Respondents' Tuberculosis Treatment Risk in 2020–2021.**

**a. Gender**

Gender is the difference in form, nature, and biological function between men and women, which determines the difference in their roles in preserving the lineage. This difference occurs as a result of their reproductive organs, which enable them to produce unique progeny. This factor significantly affects the treatment status of tuberculosis patients (4). On the basis of the results of the univariate study, it was determined that, out of a total sample of 161 TB RO patients and 161 TB SO patients, 111 RO TB patients (89%) were male, followed by 50 patients (31%) whowere female. Compared to the 161 TB SO patients, 54% of the 87 SO TB patients were male and 46% were female.Based on the research conducted, it was determined that more than half of the male TB RO patients were comparableto the female TB SO patients studied, more than half of the female TB SO patients.

**b. Age**

Age is the duration of a person's existence and can be measured using units of time in terms of chronology. Normal individuals display the same level of anatomical and physiological development regardless of age. Age is also the duration of a person's life or existence. Age also requires and effects the status of tuberculosis treatment because it determines TB patients' susceptibility, particularly in the elderly. On the basis of the results of the univariate study, it was determined that, out of a total sample of 161 TB ROpatients and 161 TB SO patients, almost all of them were adults (99%), followed by only two minors (1.2%). Similarly, TB SO affects nearly all adults 141 (88%) and children up to 12 (12%). Based on the results of the conducted research, it was determined that almost all TB patients, both RO and SO TB, infect adults rather than children; therefore, it can be stated that TB disease is more prevalent and dominant in adults due to their greater mobility and exposure to a greater number of people than children.

**c. Investigation of contact Risk Characteristics of Previous TB Treatment**

The objective of contact investigation (IK) is to increase the detection of tuberculosis cases through the early and systematic identification of individuals who have had contact with the source of TB infection. This contact

investigation activity has a significant impact on the reduction of tuberculosis incidence because it can decrease transmission rates among at-risk populations, particularly families. The investigation of these contacts is conducted on household contacts and close contacts of TB patients, especially if the TB RO patient is extremely dangerous, the severity of the disease, and especially if the infected are minors. Based on the results of the univariate study, an overall picture was derived indicating that, out of a total sample of 161 TB RO patients and 161 TB SO patients, 97 RO TB patients (60%) underwent contact investigations only and 64 patients (40%) did not undergo contact investigations. Unlike the 161 TB SO patients, 120 TB SO patients (75%) did not undertake contact investigations, followed by 41 patients (25%) who underwent contact investigations only. This study revealed a relatively high number of TB RO and TB SO patients who did not conduct contact investigations, posing a problem that needed to be addressed by identifying the factors that led to the lack of contact investigations in TB RO and SO patients. Based on the findings of the conducted research, it was determined that more than half of the TB RO patients who underwent contact investigations were inversely proportional to the TB SO patients studied, more than half of the TB SO patients who did not conduct contact investigations. The results of this study are supported by research conducted by Fitriani (2013), which found that more than half of the study sample did not conduct contact investigations regarding the contact history of these TB patients.

#### **d. Risk Characteristics of Previous TB Treatment**

Patients who have never received TB treatment or have taken anti-tuberculosis medications for less than one month (of 28 doses) are considered new TB patients. This TB patient has never been exposed to TB before, but is now afflicted due to unknowingly coming into contact with a TB patient. In addition, this new TB case has a close relationship with the status of TB treatment in order to assess and analyze the dissemination of TB cases in the community, including both RO TB and SO TB. The majority of the 161 cases of RO TB, or 53%, were not new patients, according to this study, whereas 47% of RO TB patients were newly diagnosed. In contrast to the 161 TB SO patients, the majority of the 153 SO TB patients (95%) were new TB patients, while only eight patients (5%) were not new TB patients. According to research conducted by Lilia Damayanti in 2022 (2), 32 out of 48 respondents were newly diagnosed TB patients. In addition, according to a study conducted by Manggasa (2022), 81.2% of TB SO patients were newly diagnosed TB patients.

The treatment history of tuberculosis (TB) patients plays a significant role in determining the regimen to be administered to patients, as TB drugs vary and there are numerous types, particularly if a TB patient who is already resistant requires a more in-depth examination to determine the drug sensitivity of the TB patient. Relapsed patients are tuberculosis patients who have been declared cured or who have completed treatment and who are currently diagnosed with tuberculosis based on the findings of a bacteriological or clinical examination (either due to a true relapse or reinfection). In this study, of the 161 cases of RO TB, 100 patients (62%) did not have a history of TB relapse, compared to 61 (38%) TB RO patients who had a history of TB relapse; this was similar to the 161 TB SO patients, the majority of whom did not have a history of TB relapse, 156 (97%) compared to 5 (31%) TB SO patients who had a history of TB relapse. This is consistent with research conducted by Lilia Damayanti in 2022 (2), which indicates that in the Productive Age, where the status of relapse TB treatment is not too dominant, new TB patients are new TB patients because they are infected by individuals with resistant or sensitive TB pathogens. The level of patient communication and candor can also influence the treatment status of tuberculosis (TB) patients, as the information extracted or the patient's RM will reveal whether this TB patient is newly afflicted or has been previously treated. Patients who are being treated again after failing are TB patients who have previously been treated and whose last treatment was deemed unsuccessful. This is also influenced by the level of medication adherence of TB patients

and the function of the PMO. If the medication is not taken regularly or at all, the results will be visible in the monitoring of TB patients' treatment.

**e. Characterization of Comorbidity Risk on Tuberculosis Treatment Status in the Province of West Sumatra in 2020-2021**

Diabetes mellitus is a risk factor for tuberculosis and can affect the disease's presence and response to treatment. TB can also induce glucose intolerance and worsen diabetics' glycemic control. The convergence of the two epidemics is most likely to occur in regions where health resources are scarce and the incidence of diabetes is rising globally, particularly in developing nations where tuberculosis is most prevalent and where health resources are scarcest. Diabetes is an independent risk factor for all infections of the lower respiratory tract. It is estimated that diabetes multiplies the risk of tuberculosis by 1.5-7.8. DM also has a significant impact on the treatment status of tuberculosis patients, as DM patients require a significantly longer recuperation period than other TB patients.

In this study it was found that there were 130 (81%) cases of TB RO, most of them had no known history of diabetes mellitus (dm), namely by distribution, compared to tuberculosis patients with a known history of diabetes mellitus (dm) 31 (19.2%), whereas of the 161 cases of tuberculosis, most also had no known history of diabetes mellitus (dm), namely with a frequency distribution of 108 (67%) than TB patients with known history of diabetes mellitus (DM). This is consistent with the findings of Manggasa 2022 (12) and Nurwanti 2016 (16), who discovered that the majority of respondents had a diabetes history that was unknown both before and during treatment because many refused to be examined or have their blood extracted.

HIV infection facilitates the progression of latent TB infection to active TB disease. This situation unquestionably raises a number of new issues that require greater and more serious consideration from multiple parties. Regarding the diagnosis and treatment of TB-HIV co-infection, attention must be paid to the distinctions in clinical manifestations and drug administration guidelines. Better coordination is required to control cases of TB-HIV co-infection; the TB-HIV program must be coordinated to prevent HIV in TB patients, prevent TB in HIV patients, examine patients and contacts (TB and HIV), coordinate treatment and drug supply, and manage the resulting impacts. In this study, out of 161 cases of RO TB, the majority of patients with unknown HIV status were 143 (89%) versus 18 TB RO patients who knew their HIV status. Similarly, the majority of TB SO patients with unknown HIV status were 129 (80%) versus 32 TB SO patients who knew their HIV status. This is consistent with research conducted by Ni'mal 2019 which found that more than half of respondents, or 93.3%, were unaware of their TB treatment history or HIV status. HIV infection influences the incidence of tuberculosis. This is due to the fact that HIV-positive individuals have inadequate or diminished immunity, making them susceptible to other diseases, including tuberculosis.

**3. Relationship between Age, Gender, and Characterization of Contact Investigation Risk on Tuberculosis Treatment Status in the Province of West Sumatra in 2020-2021**

**a. Relationship between Gender and Status of TB Treatment**

The p-value from the bivariate analysis was 0.00006, indicating that there is a correlation between gender and TB treatment status in the West Sumatra Province. Based on the OR value of 1.89, it was determined that males were 1.89 times more likely to be treated for tuberculosis. The results of this study are consistent with Jyothi's 2018 research, which demonstrates, with a p-value of 0.001, that gender is associated with the risk of developing pulmonary tuberculosis. Manik Parmelia 2019 (16) found, however, that there is no correlation between gender and the incidence of drug cessation among pulmonary TB patients at the Denpasar City Health Center. In the bivariate analysis, however, men had a 3.4 times greater risk of discontinuing TB treatment than women (OR=3.4, p=0.034). Gender is the characteristic that distinguishes between men and women in a population where some individuals

are at risk and others are not. This variable is also highly influential in a number of studies examining the relationship between a disease and tuberculosis; moreover, TB disease is readily transmitted via air or droplets alone.

**b. Relationship between TB Treatment Status and Contact Investigation**

The p-value from the bivariate analysis was 0.001, indicating that there is a correlation between contact investigations and TB treatment status in West Sumatra Province. Based on the OR value of 0.14, it was determined that the risk of TB treatment status was 0.14 times greater for contact investigations. This study's findings are consistent with those of Fitriani's 2013 study (6), Risk Factors Associated with the incidence of pulmonary tuberculosis (a case study at the Keuntungan Health Center, Brebes Regency, 2013), which found that a history of contact with tuberculosis patients increased the risk of developing the disease by a factor of 5,429 times. This research is also consistent with FKM UI research regarding risk factors associated with the incidence of tuberculosis in Indonesia Fitriani, 2020 (6). This is also consistent with a study conducted by Begna (2014) (1) in South East Ethiopia, where contact with active TB patients was associated with a 2.40-fold increased risk of developing tuberculosis (Hogan et al., 2020). The objective of contact investigation (IK) is to increase tuberculosis case detection through the early and systematic detection of individuals in contact with the source of TB infection.

**c. Medical history and TB treatment status correlation**

The p-value of the bivariate analysis was 0.001, indicating that there is a correlation between novel TB and TB treatment status in West Sumatra Province. Based on the OR value of 0.05, it was determined that new TB cases were at a risk of TB treatment status that was 0.05 times greater. The results of this study are consistent with research conducted by Lilia Damayanti in 2022 (2) regarding the status of Treatment Associated with the Incidence of Drug-Resistant Tuberculosis in Productive Age where the dominant status of RO TB treatment is new TB patients, indicating that the spread of RO TB cases is increasing and the majority of RO TB patients are primary (patients who have never taken TB drugs) (2). TB is reduced through their air and sputum splashes of coughing TB patients who do not conceal their mouths. If the air containing TB bacteria is inhaled, there is a chance that those nearby will contract tuberculosis; if the immune system is compromised, transmission will be facilitated. In addition, this study is consistent with research conducted by Manggasa 2022 (12) regarding the History of Treatment and Comorbid Diabetes Mellitus Associated with the Incidence of Drug-Resistant Tuberculosis, which states that TB disease can be contracted even if there is no history of prior treatment.

The p-value from the bivariate analysis was 0.001, indicating that there is a correlation between recurrent TB cases and TB treatment status in West Sumatra Province. Based on the OR value of 19.0, it was determined that having no history of tuberculosis recurrence increased the risk of TB treatment status by 19.0 times. The findings of this investigation are consistent with previous research. This study is consistent with Damayanti's 2022 study (2) regarding the status of Treatment Associated with the Incidence of Drug-resistant Tuberculosis at a Productive Age, where the status of relapsed TB treatment is not too predominant and the highest number of patients is new TB patients infected by resistant or sensitive TB germs. This indicates that the spread of tuberculosis (TB) is increasing among the general population, especially among those who are in close contact with the disease at home and in close quarters, notably through the air and droplets (sputum splashes). (2)

The bivariate analysis yielded a p-value of 0.007, indicating that there was a correlation between TB cases that did not respond to treatment and TB treatment status in West Sumatra Province. Based on the OR value of 16.4, it was determined that not having a history of drug failure increased the risk of TB treatment status by 16.4 times. The findings of this investigation are consistent with previous research. This research is also consistent with the research conducted by Manggasa 2022 (12) and regarding the History of Treatment and Comorbid Diabetes Mellitus Associated with the Incidence of Drug-Resistant Tuberculosis, which states that a person has contracted

TB disease despite having no prior treatment history. Possibilities include a history of intimate contact with TB-related organisms and TB patients, as well as dishonesty on the part of TB patients in providing information regarding previous treatment (12). Similarly, research conducted by Lilia Damayanti 2022(2) regarding the status of Treatment Associated with the Incidence of Drug-Resistant Tuberculosis in Productive Age, which concluded the same thing, supports this conclusion.

This study, however, differs from research conducted by Nurmala 2020 (15) regarding the relationship between history of tuberculosis treatment and incidence of multidrug-resistant tuberculosis (MDR TB), which states that more TB patients have failed treatment because TB patients have failed treatment based on the results of smears or cultures that have not converted after the intensive stage of treatment, but there are also some patients who require more time so that treatment can be completed. In West Sumatra Province, the bivariate analysis yielded a p-value of 0.059, indicating that there was no correlation between TB cases opting out of treatment and TB treatment status. Based on the OR value of 4.71, it was determined that the risk of TB treatment status was 4.71 times greater for individuals with no history of TB treatment discontinuation. This study differs from the research conducted by Nurmala in 2020 (15) and Nugi in 2020 (analysis of individual risk factors for multidrug-resistant tuberculosis) in South Sumatra Province, which concluded that TB patients who had discontinued treatment were 13.8 times more likely to develop RO. Therefore, health workers at puskesmas administering TB programs must always obtain comprehensive information from TB patients seeking treatment at health facilities. (14)

#### **d. Relationship between TB Treatment Status and Comorbidity**

In West Sumatra Province, the bivariate analysis yielded a p-value of 0.2, indicating that there was no correlation between Diabetes Mellitus and TB treatment status. Based on the OR value of 2.05, it was determined that males with Diabetes Mellitus are 2.05 times more likely to be treated for tuberculosis. The findings of this investigation are consistent with previous research. This study is consistent with the research conducted by Manggasa 2022 (12) regarding the History of Treatment and Comorbid Diabetes Mellitus Associated with the Incidence of Drug-Resistant Tuberculosis and Nurwanti's Research 2016 (16), which found that the majority of both cases and controls did not have diabetes mellitus after being declared cured. Diabetes mellitus is an independent risk factor for all lower respiratory tract infections, according to research conducted by Rosdiana (2017) (17) on drug-resistant pulmonary tuberculosis in patients with diabetes mellitus. DM also increases the risk of tuberculosis by 1.5 to 7.8 times compared to those without DM. In addition, the increased prevalence of diabetes is a challenge in TB control, as is the difficulty in controlling blood sugar levels in patients with both diabetes and tuberculosis (16).

The p-value from the bivariate analysis was 0.1, indicating that there was no correlation between HIV and TB treatment status in the West Sumatra Province. Based on the POR value of 1.82, it was determined that not knowing HIV status increased the risk of TB treatment by 1.82 times. This research is consistent with Trivialto 2021 regarding Risk Factors Affecting Multidrug-Resistant Tuberculosis (MDR TB), which states that HIV infection status is a factor that influences the occurrence of TB. This study is consistent with research conducted by Muna 2019 (13) on the Determinants of Tuberculosis Occurrence in People with HIV/AIDS, which states that the relationship between these two diseases is related to the immune system, which is responsible for combatting infection. HIV is a virus that can weaken the immune system, which makes it easier for other infections to infiltrate the body. In addition, HIV causes injury to the immune system, particularly in those with opportunistic TB infections (13).



#### 4. Final Risk Characterization Model of Treatment History and Comorbidity on TB Treatment Status

Logistic regression analysis was used to conduct a multivariate analysis. The purpose of this analysis is to elucidate the effect of multiple independent variables on the dependent variable. Multivariate analysis begins with the selection of variables for inclusion in the analysis, specifically variables with a p value 0.25. The analysis results demonstrate a comprehensive multivariate analysis model. Age, Contact Investigation, and Recurrence of TB emerged as the most influential variables on TB treatment status in West Sumatra Province after analyzing the candidate variables. Risk of influencing TB treatment status is 0.09 times higher for adult age, 0.23 times higher for contact investigations, and 0.05 times higher for a history of recent TB treatment.

## CONCLUSION

Based on the findings of a study involving 161 TB RO patients and 161 SO TB patients, the following conclusions were drawn about the Characterization of Risk of Treatment History and Comorbidities on TB Treatment Status in West Sumatra Province in 2020-2021: Based on the findings of a study conducted on 322 TB patients in the province of West Sumatra, the majority of respondents were adult males. The majority of contact investigation activities do not involve TB patients. Risk factors based on treatment history revealed that the majority of TB RO treatment status were not new patients, relapsed TB cases, drug failure TB cases, or drug withdrawal TB cases, and that the majority of patients were unaware of their comorbid DM and HIV status. Statistical evaluations revealed a correlation between age, gender, Contact Investigation, and tuberculosis treatment status in West Sumatra Province in 2020-2021. History of treatment (new TB, relapsed TB, TB drug failure and treatment discontinuation) is related to TB treatment status in West Sumatra Province in 2020-2021, but comorbidities (diabetes and HIV) are not. Age, contact investigations, and new TB cases are the most influential independent variables influencing the status of TB treatment in West Sumatra Province in 2020-2021.

## ACKNOWLEDGMENT

Thank you to the supervisor who provided guidance, direction, and instructions for the completion of this thesis, as well as the examiners who provided guidance and direction for the completion of this thesis. The researcher recognizes that through this study, the distribution of TB treatment status-related frequencies, relationships, and dominant factors in West Sumatra Province can be identified. Therefore, researchers eagerly anticipate constructive criticism and recommendations for the improvement of future reports. Hopefully, Allah SWT will respond to the assistance given to researchers, Aamiin. The author expects that all interested parties will find this thesis useful.

## REFERENCE

- [1] Bawonte, T. G., Mambo, C. D. and Masengi, A. S. R. (2021) 'Faktor-Faktor Yang Mempengaruhi Tuberculosis Multidrug Resistance (TB MDR)', *Jurnal e-Biomedik*, 9(1), pp. 117–125. doi: 10.35790/ebm.v9i1.31949.
- [2] Damayanti, L., Widada, W. and Adi, S. (2022) 'Status Pengobatan Berhubungan Dengan Kejadian Tuberculosis Resistan Obat Pada Usia Produktif', *Profesional Health Journal*, 3(2), pp. 138–148. Available at: <https://www.ojsstikesbanyuwangi.com/index.php/PHJ>.
- [3] Dinas Kesehatan Provinsi Sumatera Barat (2021) Laporan Audit Klinis Rumah Sakit Pelayanan TBC Resisten Obat.
- [4] Dirjen P2P Kemenkes RI (2020) 'Protokol tata laksana pasien TBC dalam masa Pandemi Covid-19.'
- [5] DPPPA Kota Bogor. (2021) Apa Perbedaan Gender dan Jenis Kelamin? Available at: <https://dpppa.kotabogor.go.id/index.php/welcome/post/single/113>.

- [6] Fitriani, N. I. (2020) 'injauan pustaka covid-19: virologi, patogenesis, dan manifestasi klinis', *Jurnal Medika Malahayati*, 4(3), pp. 1–8.
- [7] Global Tuberculosis Report 2020 (no date). Geneva: World Health Organization.
- [8] Hogan, A. B. et al. (2020) 'Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low- income and middle-income countries: a modelling study', *The Lancet Global Health*. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license, 8(9), pp. e1132–e1141. doi: 10.1016/S2214- 109X(20)30288-6.
- [9] Kemenkes RI (2016) 'Buku petunjuk TB-HIV untuk Petugas', p. 7.
- [10] Kementerian Kesehatan Republik Indonesia (2020) 'Strategi Nasional Penanggulangan Tuberkulosis di Indonesia 2020-2024', *Pertemuan Konsolidasi Nasional Penyusunan STRANAS TB*, p. 135.
- [11] Kementerian Kesehatan RI (2016) Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016: Pedoman Penanggulangan Tuberkulosis.
- [12] Manggasa, D. D. and Suharto, D. N. (2022) 'Riwayat Pengobatan dan Komorbid Diabetes Mellitus Berhubungan Dengan Kejadian Tuberkulosis Resistensi Obat', *Poltekita: Jurnal Ilmu Kesehatan*, 15(4), pp. 403–408. doi: 10.33860/jik.v15i4.659.
- [13] Muna, N. and Cahyati, W. H. (2019) 'Determinan Kejadian Tuberkulosis pada Orang dengan HIV/AIDS', *Higeia Journal of Public Health*, 3(2), pp. 168–178.
- [14] Nurdin, N. (2020) 'Analisis faktor-faktor determinan Individu terhadap Tuberculosis Multidrug Resistant (TB MDR) di Provinsi Sumatera Selatan', *Jurnal Kesehatan Komunitas*, 6(1), pp. 63–67. doi: 10.25311/keskom.vol6.iss1.385.
- [15] Nurmala, Q. P. and Habib, I. (2019) 'Hubungan Riwayat Pengobatan Tuberkulosis Dengan Insidensi Multidrug Resistant Tuberculosis (Mdr Tb)', 38. Available at: <http://repository.umy.ac.id/handle/123456789/33711>.
- [16] Nurwanti and Wahyono, B. (2016) 'Hubungan Antara Faktor Penjamu ( Host ) Dan Faktor Lingkungan ( Environment ) Dengan Kejadian Tuberkulosis Paru Kambuh ( Relaps ) Di Puskesmas Se-Kota Semarang', *Public Health Perspective Journal*, 1(1), pp. 77–87.
- [17] Parmelia, M et al (2019) 'Faktor yang berhubungan dengan Kejadian Putus Obat Pada Pasien Tuberkulosis Paru di Puskesmas Denpasar' *Jurnal Medika Udayana*, Vol. 8 No 9, September, 2019
- [18] Rosdiana, D. (2017) 'Tuberkulosis Paru Resistensi Obat dengan Komorbiditas Diabetes Mellitus', *Jurnal Kesehatan Melayu*, 1(1), p. 45. doi: 10.26891/jkm.v1i1.14.